|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5631271A
(en)
|
1986-11-29 |
1997-05-20 |
Serfontein; Willem J. |
Methods and preparations for the treatment and prophylaxis of metabolic disturbances
|
|
US5874285A
(en)
|
1996-09-13 |
1999-02-23 |
Incyte Pharmaceuticals, Inc. |
Polynucleotide encoding a novel human nm23-like protein
|
|
US6818749B1
(en)
*
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
|
JP2002535656A
(ja)
|
1999-01-23 |
2002-10-22 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
コロイド固定化種と非コロイド構造上の種との相互作用
|
|
JP5122705B2
(ja)
|
1999-01-25 |
2013-01-16 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
|
|
WO2002001230A2
(en)
|
2000-06-23 |
2002-01-03 |
Minerva Biotechnologies Corporation |
Rapid and sensitive detection of protein aggregation
|
|
CA2384713A1
(en)
|
1999-09-29 |
2001-04-05 |
Human Genome Sciences, Inc. |
Colon and colon cancer associated polynucleotides and polypeptides
|
|
JP2003535099A
(ja)
|
2000-05-26 |
2003-11-25 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
化学又は生物学的事象を検出するための信号変換器としてのメタロセン
|
|
AU7014001A
(en)
|
2000-06-23 |
2002-01-08 |
Minerva Biotechnologies Corp |
Interaction of colloid-immobilized species with species on non-colloidal structures
|
|
AUPR011700A0
(en)
|
2000-09-14 |
2000-10-05 |
Austin Research Institute, The |
Composition comprising immunogenic virus sized particles (VSP)
|
|
WO2002029411A2
(en)
|
2000-10-03 |
2002-04-11 |
Minerva Biotechnologies Corporation |
Magnetic in situ dilution
|
|
JP4335526B2
(ja)
|
2000-11-01 |
2009-09-30 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
コロイド構造体および非コロイド構造体による結合スピーシーズの検出
|
|
EP1348034B1
(en)
|
2000-11-15 |
2016-07-20 |
Minerva Biotechnologies Corporation |
Oligonucleotide identifiers
|
|
EP2322929B1
(en)
|
2000-11-27 |
2016-04-06 |
Minerva Biotechnologies Corporation |
diagnostics, drug screening and treatment for cancer
|
|
WO2003018846A1
(en)
|
2001-08-31 |
2003-03-06 |
Minerva Biotechnologies Corporation |
Affinity tag modified particles
|
|
EP1434584A2
(en)
|
2001-09-05 |
2004-07-07 |
Minerva Biotechnologies Corporation |
Compositions and methods of treatment of cancer
|
|
JP2005507876A
(ja)
|
2001-09-05 |
2005-03-24 |
ミナーバ バイオテクノロジーズ コーポレイション |
癌を治療する組成物および方法
|
|
US20050163784A1
(en)
|
2002-06-17 |
2005-07-28 |
Valentijn Linda J. |
Novel cancer therapies
|
|
CA2491017A1
(en)
|
2002-07-03 |
2004-01-15 |
Immunogen, Inc. |
Antibodies to non-shed muc1 and muc16, and uses thereof
|
|
CA2537263C
(en)
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
|
WO2004050860A2
(en)
|
2002-12-04 |
2004-06-17 |
Diadexus, Inc. |
Compositions, splice variants and methods relating to colon specific genes and proteins
|
|
JP2006517674A
(ja)
|
2002-12-20 |
2006-07-27 |
ミネルバ バイオテクノロジーズ コーポレーション |
ナノ粒子を含む光学デバイスおよび方法
|
|
US20080064680A1
(en)
|
2004-09-14 |
2008-03-13 |
Bamdad Cynthia C |
Methods for Diagnosis and Treatment of Cancer
|
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
|
CA2610292C
(en)
|
2005-03-30 |
2015-06-02 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
|
CA2611728A1
(en)
|
2005-06-08 |
2006-12-14 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with cancer therapy
|
|
WO2007072221A2
(en)
|
2005-11-10 |
2007-06-28 |
Aurelium Biopharma Inc. |
Surface marker-directed cancer therapeutics
|
|
CN101652469B
(zh)
|
2006-12-06 |
2014-04-16 |
米纳瓦生物技术公司 |
用于鉴定和操作细胞的方法
|
|
US20100254996A1
(en)
|
2007-06-18 |
2010-10-07 |
Medimmune, Llc |
Synergistic treatment of cells that express epha2 and erbb2
|
|
WO2009042815A1
(en)
|
2007-09-25 |
2009-04-02 |
Minerva Biotechnologies Corp. |
Methods for treatment of cancer
|
|
WO2009042814A1
(en)
|
2007-09-25 |
2009-04-02 |
Minerva Biotechnologies Corp. |
Early diagnosis and treatment of drug resistance in muc1-positive cancer
|
|
US11202775B2
(en)
|
2007-09-25 |
2021-12-21 |
Minerva Biotechnologies Corporation |
Methods for treatment of cancer
|
|
DK2334703T3
(en)
*
|
2008-09-17 |
2015-10-05 |
Innate Pharma |
Configurations and methods for detection of tlr3
|
|
US20170204191A1
(en)
|
2008-10-06 |
2017-07-20 |
Cynthia C. Bamdad |
Muc1* antibodies
|
|
US20110195089A1
(en)
|
2008-10-08 |
2011-08-11 |
The Adminstrators Of The Tulane Educational Fund |
Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
|
|
WO2010042891A2
(en)
|
2008-10-09 |
2010-04-15 |
Minerva Biotechnologies Corporation |
Method for inducing pluripotency in cells
|
|
US20100179213A1
(en)
|
2008-11-11 |
2010-07-15 |
Mirna Therapeutics, Inc. |
Methods and Compositions Involving miRNAs In Cancer Stem Cells
|
|
SG176801A1
(en)
|
2009-06-11 |
2012-01-30 |
Minerva Biotechnologies Corp |
Methods for culturing stem and progenitor cells
|
|
EP3228629A1
(en)
|
2010-06-16 |
2017-10-11 |
Minerva Biotechnologies Corporation |
Reprogramming cancer cells
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2686418A4
(en)
|
2011-03-17 |
2015-04-22 |
Minerva Biotechnologies Corp |
METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
|
|
EP2707021B1
(en)
|
2011-05-09 |
2024-02-21 |
Minerva Biotechnologies Corporation |
Genetically engineered growth factor variants
|
|
EP2768945B1
(en)
|
2011-10-17 |
2022-01-05 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
|
US20240247229A1
(en)
|
2011-10-17 |
2024-07-25 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
|
WO2013123084A1
(en)
|
2012-02-13 |
2013-08-22 |
Minerva Biotechnologies Corporation |
Method for detecting circulating fetal cells
|
|
CA2864872C
(en)
|
2012-02-24 |
2022-07-05 |
Alteogen Inc. |
Modified antibody in which motif comprising cysteine residue is bound
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
JP6748430B2
(ja)
|
2012-07-13 |
2020-09-02 |
ミネルバ バイオテクノロジーズ コーポレーション |
より未分化状態への細胞の誘導方法
|
|
CN111849874A
(zh)
|
2012-07-24 |
2020-10-30 |
米纳瓦生物技术公司 |
Nme变体物种表达和抑制
|
|
CN104717980A
(zh)
|
2012-08-14 |
2015-06-17 |
米纳瓦生物技术公司 |
干细胞增强疗法
|
|
CA2886161A1
(en)
*
|
2012-09-29 |
2014-04-03 |
The Trustees Of The University Of Pennsylvania |
Veterinary composition and methods for non-surgical neutering and castration
|
|
US20160326263A1
(en)
*
|
2013-02-20 |
2016-11-10 |
Minerva Biotechnologies Corporation |
NME Inhibitors and Methods of Using NME Inhibitors
|
|
IL240695B2
(en)
|
2013-02-20 |
2024-03-01 |
Minerva Biotechnologies Corp |
Nme inhibitors and methods of using nme inhibitors
|
|
TWI659210B
(zh)
|
2013-08-12 |
2019-05-11 |
Minerva Biotechnologies Corporation |
加強腫瘤生長的方法
|
|
CN106414726A
(zh)
|
2014-04-07 |
2017-02-15 |
米纳瓦生物技术公司 |
抗nme抗体
|
|
CA2976089C
(en)
|
2015-02-10 |
2026-01-13 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
US20170106046A1
(en)
|
2015-03-03 |
2017-04-20 |
Minerva Biotechnologies Corporation |
Method for diagnosing and treating cancer using naive state stem cell specific genes
|
|
AU2016287603A1
(en)
|
2015-07-01 |
2018-01-25 |
Minerva Biotechnologies Corporation |
Method of stem cell-based organ and tissue generation
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
JP2019515643A
(ja)
|
2015-09-23 |
2019-06-13 |
ミネルバ バイオテクノロジーズ コーポレーション |
幹細胞分化剤のスクリーニング方法
|
|
WO2018010140A1
(zh)
|
2016-07-14 |
2018-01-18 |
中国科学院生物物理研究所 |
I型干扰素受体抗体及其用途
|
|
WO2018054240A1
(en)
|
2016-09-20 |
2018-03-29 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pcsk9 antibodies
|
|
JP2020500031A
(ja)
*
|
2016-10-11 |
2020-01-09 |
ミネルバ バイオテクノロジーズ コーポレーション |
ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
|
|
EP3600451B1
(en)
|
2017-03-29 |
2025-12-24 |
Minerva Biotechnologies Corporation |
Agents for differentiating stem cells and treating cancer
|
|
WO2019104306A1
(en)
|
2017-11-27 |
2019-05-31 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies and direct use of cleavage enzyme
|
|
WO2019126357A1
(en)
|
2017-12-19 |
2019-06-27 |
Minerva Biotechnologies Corporation |
Agents for treating cancer and methods for identifying said agents
|
|
CN112272677B
(zh)
|
2018-02-26 |
2024-10-29 |
米纳瓦生物技术公司 |
使用抗muc1＊抗体的诊断方法
|
|
US20200405832A1
(en)
|
2018-03-09 |
2020-12-31 |
Minerva Biotechnologies Corporation |
Method for anti-muc1* car t cell stimulation
|
|
JP2022527144A
(ja)
|
2019-01-11 |
2022-05-31 |
ミネルヴァ バイオテクノロジーズ コーポレーション |
抗可変ｍｕｃ１＊抗体およびその使用
|
|
EP3920693A4
(en)
*
|
2019-02-04 |
2022-10-05 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
|
|
CN116367857A
(zh)
*
|
2020-06-08 |
2023-06-30 |
米纳瓦生物技术公司 |
抗nme抗体及治疗癌症或癌症转移的方法
|
|
KR20230028796A
(ko)
|
2020-06-26 |
2023-03-02 |
미네르바 바이오테크놀로지 코포레이션 |
항-nme 항체 및 암 또는 암 전이의 치료 방법
|
|
CA3183958A1
(en)
|
2020-06-26 |
2021-12-30 |
Minerva Biotechnologies Corporation |
Methods for deriving dopaminergic neurons from pluripotent stem cells
|
|
CN116234828A
(zh)
|
2020-07-29 |
2023-06-06 |
米纳瓦生物技术公司 |
抗可变muc1*抗体及其用途
|
|
KR20250009592A
(ko)
|
2022-04-12 |
2025-01-17 |
미네르바 바이오테크놀로지 코포레이션 |
항-가변 muc1* 항체 및 그의 용도
|
|
EP4522206A1
(en)
|
2022-05-09 |
2025-03-19 |
Minerva Biotechnologies Corporation |
Chimeric antigen receptor and il-18 receptor compositions and methods of use therein
|
|
US20240261406A1
(en)
|
2023-02-02 |
2024-08-08 |
Minerva Biotechnologies Corporation |
Chimeric antigen receptor compositions and methods for treating muc1* diseases
|